A new global survey of diabetes patients conducted by Roche has revealed a desire for predictive tools to help them manage their condition.

The survey gathered responses from 4,326 patients with diabetes across 22 countries, with questions that sought to identify the emotional and logistical challenges faced in diabetes patients’ daily lives.

Over half of respondents said that living with diabetes affected their ability to partake in sports, daily chores, and their ability to fall asleep and feel well-rested the following day.

To mitigate the burdens associated with living with diabetes, eight in 10 respondents said they would value predictive tools that were able to, for example, predict glucose changes before they occur. Meanwhile, 46% said they would feel more in control of their disease in their everyday lives if they could see trends before they turn into problems. 

Roche noted that these findings highlight the need for smarter diabetes management solutions that move beyond reporting current glucose levels to providing insights to help diabetes patients with factors including “flexibility, freedom, and peace of mind”.

Smarter tools that predict glucose levels could help people with diabetes feel “safer, more confident and more in control”, Roche added.

Roche Diagnostics’ Claire Marriott, medical affairs lead for the EMEA-LATAM regions, said: "This survey brings to light the daily and long-term challenges faced by people with diabetes.

“By better understanding the reality of people living with diabetes, we can work to ease the daily burden of diabetes management, support them in reducing their risk of long-term complications, and help them feel more in control of their lives."

Roche plans to share in-depth findings from the survey alongside new real-world evidence comparing predictive technology with standard continuous glucose monitoring (CGM) systems that only provide real-time information at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), taking place in Barcelona on 11 March 2026.

By 2050, diabetes prevalence is projected to rise by 46%, affecting one in eight adults, equating to approximately 853 million people worldwide.

The dominant modalities used for diabetes patients to manage their condition include glucose meters or CGMs for tracking blood sugar levels to prevent high (hyperglycaemia) or low (hypoglycaemia) events from occurring.

GlobalData anaysis reveals that the CGM market is growing at a CAGR of 9.85% and projected to reach a valuation of $15.69bn in 2035.

According to a GlobalData market model, Abbott was the CGM market leader in the US in 2025 with a 48.5% share, closely followed by Dexcom with a market share of 44.7%.